【Abstract】 Objective To study the effect of rosuvastatin in treatment of heart disease complicated with hyperlipidemia and its effect on level of hsCRP, MFGE8 and Klotho. Methods From July 2015 to June 2016, 170 patients with CHD complicated with hyperlipidemia were divided into experimental group and control group according to admission order, and 85 patients in each group. The control group was treated with routine therapy, and the observation group was taken rosuvastatin on this basis of control group. The levels of serum high sensitive Creactive protein (hsCRP), milk fat globulin epidermal growth factor 8 (MFGE8) and Klotho gene were measured before and after the treatment. The clinical efficacy was compared between the two groups. Results The total clinical efficacy of the observation group was significantly higher than that of the control group ［9059% (77/85) VS 7765% (66/85)］ (P＜005). The low density lipoprotein cholesterol (LDLC), triglyceride (TG), total cholesterol (TC) and triglyceride (TG) of experimental group were significantly higher than that of control group ［(281±025) mmol/L, (131±053) mmol/L, (432±035) mmol / L VS (486±087) mmol/L, (221±061) mmol/L, (515±065) mmol/L］. The high density lipoprotein cholesterol (HDLC) of experimental group was higher than that of control group. The level of hsCRP in experimental group was significantly lower than those in the control group (P＜005). MFGE8 and Klotho levels of experimental group were significantly higher than those in the control group (P＜005). Conclusion Treatment with rosuvastatin in patients with coronary heart disease and hyperlipidemia can effectively regulate the levels of hsCRP, MFGE8 and Klotho, and the clinical curative effect is good.